Opinion|Videos|April 4, 2025
Safety Considerations for IL-17 Inhibitors
Panelists discuss how IL-17 inhibitors are generally well-tolerated, but common adverse effects include infections, particularly candidiasis, and potential increased suicidal ideation risk. Patients should be informed of candidiasis risk, especially with bimekizumab (Gordon, 2022), and monitored for mood changes, as IL-17s and IL-23s may impact mental health (Blauvelt, 2023). Open discussions help assess risks while ensuring treatment benefits.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Now let’s talk about the safety of the IL-17 inhibitor class. What is the overall safety of these agents, and what are some common adverse effects?
- How do you talk to your patients about some of the specific adverse events observed with some of these agents such as infections/candidiasis or increased risk of suicidal ideation?
- Suicidal ideation risk of IL-17s and IL-23s (Blauvelt, 2023)
- Candidiasis recurrence with bimekizumab (Gordon, 2022)
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Related Content
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Clascoterone 5% Delivers Strong Phase 3 Hair-Growth Results
2
Reviewing Type 2 Inflammation Through a Different Lens
3
Derm Dispatch: What 'Free to Be Me' Means to Tori Spelling and Stella McDermott
4
Alpha-9 Begins First-in-Human Trial of MC1R-Targeted Radiotherapeutic
5
